1035 / 1224
Phase II or retrospective cohorts
Author; year
Design
Pts
Dose/frx
m-FU
Local control
2-years (%)
Survival
1-, 2- years (%)
Mendez-
Romero 2006
Phase I/II
17
3x10-12.5 Gy
13 mts
86
85, 62
Rusthoven 2009
Phase I/II
47
3x12-20 Gy
16 mts
92
77, 30
Lee 2009
Phase I
68
6x4.6-10 Gy
11 mts
71 (1-yr)
79, 41 (3 yr.)
Goodman 2010
Phase I
19
1x18-30 Gy
17 mts
75
62, 49
Rule 2010
Phase I
27
3x10 Gy,
5x10 Gy,
5x12 Gy
20 mts
56
89
100
90, 50
78, 67
75, 56
Chang 2011
Retrospect
65
2-3x20 Gy
55
38 (2-yr)
77,45
Scorsetti 2013
Phase II
61
3x25 Gy
12
91
83,38
Comito 2014
Phase II
42
4x12 –
3x25 Gy
24
80
80, 65
DeVin 2014
Retrospect
77
10x4-5 Gy
12
33
32 (3-yr)
Fode
Retrospect
225
3x15-22.5
29
LR: 13
80, 58